Serum monocyte chemoattactant protein-1 level and spinal tuberculosis susceptibility

doi:10.3969/j.issn.2095-4344.2013.30.014

Abstract

Abstract:

BACKGROUND: The monocyte chemoattactant protein-1 gene polymorphism is associated with spinal tuberculosis susceptibility.
OBJECTIVE: To investigate the association between serum monocyte chemoattactant protein-1 expression level and spinal tuberculosis susceptibility in Han population of Hunan province.
METHODS: The patients with spinal tuberculosis and the healthy volunteers were recruited in Xiangya Hospital of Central South University from December 2004 to December 2010. The empty peripheral venous blood 2 mL were collected from the subjects in early morning, then the monocyte chemoattactant protein-1-362 genotypes were detected by polymerase chain reaction and DNA sequencing technology. And the serum monocyte chemoattactant protein-1 level was detected by enzyme linked immunosorbent assay technology. The ROC curve was used for diagnostic tests to calculate diagnostic threshold value of serum monocyte chemoattactant protein-1 level to spinal tuberculosis susceptibility, and to analyze the diagnostic titer.
RESULTS AND CONCLUSION: 208 patients with spinal tuberculosis and 210 healthy volunteers were included. The serum monocyte chemoattactant protein-1 level of the spinal tuberculosis patients was significantly higher than that of the healthy volunteers [(134.58±51.63) ng/L vs. (39.18±17.45) ng/L, P < 0.01]. The serum monocyte chemoattactant protein-1 level could not be affected by gender, but over-expressed in patients with monocyte chemoattactant protein-1-362-CC genotypes. The serum monocyte chemoattactant protein-1 level higher than 101.65 ng/L indicated that the patients might suffered from spinal tuberculosis (sensitivity: 85.5%, specificity: 94.3%, Youden index: 0.799, area under curve of ROC: 0.946, 95% confidence interval: 0.916-0.975, P < 0.01). The serum monocyte chemoattactant protein-1 level may be associated with spinal tuberculosis susceptibility in Han population of Hunan province, highly expressed serum monocyte chemoattactant protein-1 can be used as one of the indicators for the diagnosis of spinal tuberculosis.

Key words: bone and joint implants, basic experiment of spinal cord injury, cytokines, serum monocyte chemoattactant protein-1, gene polymorphism, spinal tuberculosis, susceptibility, inflammatory response, diagnosis, other grants-supported paper

CLC Number:

R318

Guo Chao-feng, Zhang Hong-qi, Gao Qi-le, Tang Ming-xing, Liu Shao-hua, Deng Ang, Wang Yu-xiang, Lu Shi-jin, Li Jin-song, Yin Xin-hua. Serum monocyte chemoattactant protein-1 level and spinal tuberculosis susceptibility[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(30): 5503-5510.

Figures/Tables 4

References

[1] Ramsay A, Steingart KR, Cunningham J, et al. Translating tuberculosis research into global policies: the example of an international collaboration on diagnostics. Int J Tuberc Lung Dis. 2011;15(10):1283-1293.

[2] Schirmer P, Renault CA, Holodniy M. Is spinal tuberculosis contagious? Int J Infect Dis. 2010;14(8):e659-666.

[3] Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Annu Rev Pathol. 2012;7:353-384.

[4] Zárate-Bladés CR, Rodrigues RF, Souza PR, et al. Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis. Hum Vaccin Immunother. In press.

[5] Raja A. Immunology of tuberculosis. Indian J Med Res. 2004; 120(4):213-232.

[6] Jo EK, Park JK, Dockrell HM. Dynamics of cytokine generation in patients with active pulmonary tuberculosis. Curr Opin Infect Dis. 2003;16(3):205-210.

[7] Thye T, Nejentsev S, Intemann CD, et al. MCP-1 promoter variant -362C associated with protection from pulmonary tuberculosis in Ghana, West Africa. Hum Mol Genet. 2009; 18(2):381-388.

[8] 张宏其,高琪乐,郭超峰,等.单核细胞趋化蛋白-1基因多态性对脊柱结核易感性的影响[J].中国矫形外科杂志,2012,20(9):843- 846.

[9] Scott HM, Flynn JL. Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression. Infect Immun. 2002;70(11):5946-5954.

[10] Saukkonen JJ, Bazydlo B, Thomas M, et al. Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun. 2002;70(4):1684-1693.

[11] Peters W, Scott HM, Chambers HF, et al. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2001; 98(14):7958-7963.

[12] Arias MA, Pantoja AE, Jaramillo G, et al. Chemokine receptor expression and modulation by Mycobacterium tuberculosis antigens on mononuclear cells from human lymphoid tissues. Immunology. 2006;118(2):171-184.

[13] Flores-Villanueva PO, Ruiz-Morales JA, Song CH, et al. A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis. J Exp Med. 2005;202(12):1649-1658.

[14] Buijtels PC, van de Sande WW, Parkinson S, et al. Polymorphism in CC-chemokine ligand 2 associated with tuberculosis in Zambia. Int J Tuberc Lung Dis. 2008;12(12): 1485-1488.

[15] Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313-326.

[16] Ajuebor MN, Flower RJ, Hannon R, et al. Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model. J Leukoc Biol. 1998;63(1): 108-116.

[17] Palframan RT, Jung S, Cheng G, et al. Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med. 2001;194(9): 1361-1373.

[18] Nio Y, Yamauchi T, Iwabu M, et al. Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice. Diabetologia. 2012;55(12):3350-3358.

[19] Daly C, Rollins BJ. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation. 2003;10(3-4):247-257.

[20] Gu L, Rutledge B, Fiorillo J, et al. In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol. 1997;62(5):577-580.

[21] Dawson J, Miltz W, Mir AK, et al. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets. 2003;7(1):35-48.

[22] Conductier G, Blondeau N, Guyon A, et al. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol. 2010;224 (1-2):93-100.

[23] Salem ML, El-Naggar SA, Kadima A, et al. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine. 2006;24(24):5119- 5132.

[24] Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87(13):5134-5138.

[25] Standiford TJ, Kunkel SL, Phan SH, et al. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. J Biol Chem. 1991;266(15): 9912-9918.

[26] Brown Z, Strieter RM, Neild GH, et al. IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells. Kidney Int. 1992;42(1):95-101.

[27] Barna BP, Pettay J, Barnett GH, et al. Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor (TNF) or antibody to the 55-kDa TNF receptor. J Neuroimmunol. 1994;50(1):101-107.

[28] Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev. 2003;14(6):467-477.

[29] Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999;259(2):344-348.

[30] Matsukawa A, Lukacs NW, Standiford TJ, et al. Adenoviral-mediated overexpression of monocyte chemoattractant protein-1 differentially alters the development of Th1 and Th2 type responses in vivo. J Immunol. 2000;164(4):1699-1704.

[31] Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354(6):610-621.

[32] Karpus WJ, Lukacs NW, Kennedy KJ, et al. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol. 1997;158(9):4129-4136.

[33] Gu L, Tseng S, Horner RM, et al. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000;404(6776):407-411.

[34] Chensue SW, Warmington KS, Lukacs NW, et al. Monocyte chemotactic protein expression during schistosome egg granuloma formation. Sequence of production, localization, contribution, and regulation. Am J Pathol. 1995;146(1):130-138.

[35] Handel TM, Domaille PJ. Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry. 1996;35(21):6569-6584.

[36] Mendez A, Hernandez-Pando R, Contreras S, et al. CCL2, CCL18 and sIL-4R in renal, meningeal and pulmonary TB; a 2 year study of patients and contacts. Tuberculosis (Edinb). 2011;91(2):140-145.

[37] 汤贤英,陈松林,罗军敏,等.单核细胞趋化蛋白-1及其受体在结核性胸膜炎患者中的表达[J].中国综合临床,2009,25(3):273- 275.

[38] 徐珍娥,解元元,陈军华,等.重庆汉族儿童单核细胞趋化蛋白1基因多态性及表达水平与结核病易感性的关系[J].中华儿科杂志, 2009,47(3):200-203.

[39] Hussain R, Ansari A, Talat N, et al. CCL2/MCP-I genotype- phenotype relationship in latent tuberculosis infection. PLoS One. 2011;6(10):e25803.

[40] Hasan Z, Cliff JM, Dockrell HM, et al. CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis. PLoS One. 2009;4(12):e8459.

[41] Neyrolles O, Quintana-Murci L. Sexual inequality in tuberculosis. PLoS Med. 2009;6(12):e1000199.

[42] Lienhardt C, Fielding K, Sillah JS, et al. Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa. Int J Epidemiol. 2005;34(4):914- 923.

[43] Feng JY, Huang SF, Ting WY, et al. Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study. Clin Microbiol Infect. 2012; 18(9):E331-337.

[44] Connolly M, Nunn P. Women and tuberculosis. World Health Stat Q. 1996;49(2):115-119.

[45] Hudelson P. Gender differentials in tuberculosis: the role of socio-economic and cultural factors. Tuber Lung Dis. 1996; 77(5):391-400.

[46] Johansson E, Long NH, Diwan VK, et al. Gender and tuberculosis control: perspectives on health seeking behaviour among men and women in Vietnam. Health Policy. 2000;52(1):33-51.

[47] 陈伟,王雪静,王黎霞,等.全国五省结核病与性别关系的研究[J].中国防痨杂志,2010,32(9):534-539.

[48] Zakharyan R, Boyajyan A, Arakelyan A, et al. Monocyte chemoattractant protein-1 in schizophrenia: -2518A/G genetic variant and protein levels in Armenian population. Cytokine. 2012;58(3):351-354.

[49] Wang L, Yang L, Gao L, et al. A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with psoriasis. Int J Immunogenet. 2008;35(1): 45-49.

[50] Tucci M, Barnes EV, Sobel ES, et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 2004;50(6):1842-1849.

[51] Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999;10(1):61-86.

[52] Page SH, Wright EK Jr, Gama L, et al. Regulation of CCL2 expression by an upstream TALE homeodomain protein-binding site that synergizes with the site created by the A-2578G SNP. PLoS One. 2011;6(7):e22052.

[53] Ben-Selma W, Harizi H, Boukadida J. MCP-1-2518 A/G functional polymorphism is associated with increased susceptibility to active pulmonary tuberculosis in Tunisian patients. Mol Biol Rep. 2011;38(8):5413-5419.